Tumor marker study: the Transamerica experience 1990-1995
Related Experiment Video
Updated: Jul 26, 2026
09:32
A Next-generation Tissue Microarray (ngTMA) Protocol for Biomarker Studies
Published on: September 23, 2014
Journal of Insurance Medicine (New York, N.Y.)
|December 8, 1996
Abstract
Background:
From the fall of 1990 through January 1995 Transamerica Occidental Life screened applicants for life insurance for cancer with Tumor Associated Antigen (TAA).
Results:
110,299 applicants were tested and in 13,829 positive levels of TAA were found. Of this latter number, 255 applicants were declined following various levels of evaluation.
Conclusions:
We concluded that TAA screening was neither sensitive, nor specific enough for a screening tool for life insurance.
